SEC
SlamSEC
Search
Browse
Earnings
GRI Bio, Inc.
Nasdaq:
GRI
Pharmaceutical Preparations
·
LA JOLLA, CA
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Summary Financials
GRI Bio, Inc. — SlamSEC
Revenue
$100,000
FY 2021
Adj. EBITDA
-$8.2M
-8231.0% margin
FY 2025
Net Income
-$8.2M
-8207.0% margin
FY 2025
EPS (Diluted)
-$1545.55
FY 2025
Stock Price
$2.71
+9.3%
2026-03-10
52W Range
$2.10 – $311.36
P/E Ratio
-0.0x
Market Cap
$3.9M
Cash
$5.0M
FY 2025
Total Debt
$616,000
FY 2021
Net Cash
$4.4M
FY 2021
Enterprise Value
-$495,971.41
Debt / EBITDA
0.5x
FY 2021
EV / EBITDA
0.1x
Employees
—
CEO
Hertz Walter Marc
CFO
Kelly Leanne